Plasma cfDNA abundance as a prognostic biomarker for higher risk of death in geriatric cardiovascular patients

[1]  A. Bonfigli,et al.  Low circulating levels of miR-17 and miR-126-3p are associated with increased mortality risk in geriatric hospitalized patients affected by cardiovascular multimorbidity , 2023, GeroScience.

[2]  F. B. Clausen,et al.  Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives , 2023, Current opinion in lipidology.

[3]  Tetiana A Berezina,et al.  Cell-free DNA as a plausible biomarker of chronic kidney disease. , 2023, Epigenomics.

[4]  Xiaoguang Pan,et al.  Plasma extrachromosomal circular DNA is a pathophysiological hallmark of short‐term intensive insulin therapy for type 2 diabetes , 2023, Clinical and translational medicine.

[5]  A. Deane,et al.  Cell-free DNA as a potential biomarker for acute myocardial infarction: A systematic review and meta-analysis , 2023, International journal of cardiology. Heart & vasculature.

[6]  P. Missier,et al.  Researching multimorbidity in hospital: can we deliver on the promise of health informatics? , 2023, European Geriatric Medicine.

[7]  B. Fougère,et al.  High Prevalence of Geriatric Conditions Among Older Adults With Cardiovascular Disease , 2023, Journal of the American Heart Association.

[8]  A. Bonfigli,et al.  Biomarkers of cell damage, neutrophil and macrophage activation associated with in-hospital mortality in geriatric COVID-19 patients , 2022, Immunity & ageing : I & A.

[9]  A. Bonfigli,et al.  Improving the prognostic value of multimorbidity through the integration of selected biomarkers to the comprehensive geriatric assessment: An observational retrospective monocentric study , 2022, Frontiers in Medicine.

[10]  P. Simon,et al.  Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA , 2022, bioRxiv.

[11]  Zongan Liang,et al.  Clinical profile analysis and nomogram for predicting in-hospital mortality among elderly severe community-acquired pneumonia patients with comorbid cardiovascular disease: a retrospective cohort study , 2022, BMC Pulmonary Medicine.

[12]  Shih-Yi Lin,et al.  Prediction of Mortality in Older Hospitalized Patients after Discharge as Determined by Comprehensive Geriatric Assessment , 2022, International journal of environmental research and public health.

[13]  Hai Hu,et al.  Circulating Cell-free DNA in Serum as a Marker for the Early Detection of Tumor Recurrence in Breast Cancer Patients. , 2022, Cancer diagnosis & prognosis.

[14]  Glen C Jickling,et al.  Cell-Free DNA in Ischemic Stroke. , 2022, Stroke.

[15]  Jae Hoon Lee,et al.  Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer , 2021, Biomedicines.

[16]  J. Krasić,et al.  Impact of Preanalytical and Analytical Methods on Cell-Free DNA Diagnostics , 2021, Frontiers in Cell and Developmental Biology.

[17]  G. Costa,et al.  Properties and Application of Cell-Free DNA as a Clinical Biomarker , 2021, International journal of molecular sciences.

[18]  A. Bonfigli,et al.  Prognostic Interplay of Functional Status and Multimorbidity Among Older Patients Discharged From Hospital. , 2021, Journal of the American Medical Directors Association.

[19]  G. Sanson,et al.  Predictors of short- and long-term mortality among acutely admitted older patients: role of inflammation and frailty , 2021, Aging Clinical and Experimental Research.

[20]  A. Kimmoun,et al.  Long-term mortality of elderly patients after intensive care unit admission for COVID-19 , 2021, Intensive Care Medicine.

[21]  S. Yao,et al.  Frailty related all-cause mortality or hospital readmission among adults aged 65 and older with stage-B heart failure inpatients , 2021, BMC Geriatrics.

[22]  G. Bourque,et al.  Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity , 2021, Med.

[23]  P. Garagnani,et al.  The role of extracellular DNA in COVID-19: Clues from inflamm-aging , 2020, Ageing Research Reviews.

[24]  T. Lehtimäki,et al.  Circulating cell-free DNA level predicts all-cause mortality independent of other predictors in the Health 2000 survey , 2020, Scientific Reports.

[25]  M. Stumvoll,et al.  Increased circulating cell-free DNA in insulin resistance. , 2020, Diabetes & metabolism.

[26]  T. Strandberg,et al.  Toward a geriatric approach to patients with advanced age and cardiovascular diseases: position statement of the EuGMS Special Interest Group on Cardiovascular Medicine , 2019, European Geriatric Medicine.

[27]  T. Peretz,et al.  Life and death of circulating cell-free DNA , 2019, Cancer biology & therapy.

[28]  Chia-Ing Li,et al.  Frailty, transition in frailty status and all-cause mortality in older adults of a Taichung community-based population , 2019, BMC Geriatrics.

[29]  S. Kingsmore,et al.  Evaluating the discriminating capacity of cell death (apoptotic) biomarkers in sepsis , 2018, Journal of Intensive Care.

[30]  Jiawei Yang,et al.  Correlations of Circulating Cell‐Free DNA With Clinical Manifestations in Acute Myocardial Infarction , 2018, The American journal of the medical sciences.

[31]  F. Formiga,et al.  High comorbidity, measured by the Charlson Comorbidity Index, associates with higher 1-year mortality risks in elderly patients experiencing a first acute heart failure hospitalization , 2018, Aging Clinical and Experimental Research.

[32]  M. Dietrich,et al.  Predicting 1-year disability and mortality of injured older adults. , 2018, Archives of gerontology and geriatrics.

[33]  S. Khier,et al.  Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature , 2018, Future science OA.

[34]  Taura L. Barr,et al.  Circulating extracellular DNA levels are acutely elevated in ischaemic stroke and associated with innate immune system activation , 2017, Brain injury.

[35]  F. Cunha,et al.  Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis , 2016, PloS one.

[36]  S. Dunlay,et al.  Multimorbidity in Older Patients with Cardiovascular Disease , 2016, Current Cardiovascular Risk Reports.

[37]  C. Ronco,et al.  The Role of Cell-Free Plasma DNA in Critically Ill Patients with Sepsis , 2015, Blood Purification.

[38]  A. Bonfigli,et al.  The Report-AGE project: a permanent epidemiological observatory to identify clinical and biological markers of health outcomes in elderly hospitalized patients in Italy , 2015, Aging Clinical and Experimental Research.

[39]  T. Lehtimäki,et al.  Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey. , 2014, Atherosclerosis.

[40]  Huimin Wang,et al.  Cell-Free Circulating DNA: A New Biomarker for the Acute Coronary Syndrome , 2013, Cardiology.

[41]  K. Hadhoud,et al.  Assessment of Cell-Free DNA with Microvascular Complication of Type II Diabetes Mellitus, Using PCR and Elisa , 2010, Nucleosides, nucleotides & nucleic acids.

[42]  V. Pettilä,et al.  Association of cell-free plasma DNA with hospital mortality and organ dysfunction in intensive care unit patients , 2007, Intensive Care Medicine.

[43]  H. Reber,et al.  Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. , 2006, Clinical chemistry.

[44]  K. Tsao,et al.  Elevated cell-free serum DNA detected in patients with myocardial infarction. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[45]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.